title: Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention.
abstract: Persistent infection of High Risk (HR) Human papillomavirus (HPV) infection can lead to cervical cancer. The HPV genotypes are found worldwide, but important regional variations have been found. For a population-based HPV type prevalence study to assess the effect of existing and new prevention methods, frequently updated information on the burden of cervical cancer is essential. We evaluated the prevalence of HPV genotypes in a volunteer population screened for cervical cancer at the Local Health Unit (LHU) of Lecce. A total of 9,720 women were studied. The tests were performed by INNO-Lipa HPV Genotyping and LINEAR ARRAY HPV Genotyping Test. The overall HPV prevalence was 29.7% (95% CI, 28.8-30.6) for any HPV DNA. The prevalent type for all age groups was HPV 16 (7.4%; CI, 6.9-7.9) followed by HPV 31 (3.4%; CI, 3.0-3.7), 51 (3.0%; CI, 2.6-3.3), 52 (2.7%; CI, 2.3-3.0) and 58 (2.4%; CI, 2.1-2.7). HPV 53 was the most common low-risk HPV type with prevalence rate of 3.5 (CI, 3.1-3.8), followed by HPV 66 (3.0; CI, 2.6-3.3), 6 (2.9; CI, 2.6-3.2) and 42 (2.5; CI, 2.2-2.8). Multiple infections were present in 13.6% of HPV-tested women (CI, 12.9-14.3). Among these, the most common combination was of HPV 16 and HPV 52 genotypes. This study reports high prevalence of HPV infection and may serve as a valuable reference for assessing the impact of HPV vaccination programs. Furthermore, it supports the need for new vaccines that contain the most common HPV genotypes present in the population.
authors.affiliation: Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Lecce, Italy. marcello.guido@unisalento.it
authors.forename: Marcello
authors.initials: M
authors.lastname: Guido
authors.forename: Andrea
authors.initials: A
authors.lastname: Tinelli
authors.forename: Antonella
authors.initials: A
authors.lastname: De Donno
authors.forename: Anna Rita
authors.initials: AR
authors.lastname: Bruno
authors.forename: Luigi
authors.initials: L
authors.lastname: Tagliaferro
authors.forename: Alberto
authors.initials: A
authors.lastname: Fedele
authors.forename: Aniello
authors.initials: A
authors.lastname: Carbone
authors.forename: Paola
authors.initials: P
authors.lastname: Menegazzi
authors.forename: Valerio
authors.initials: V
authors.lastname: Aprile
authors.forename: Marilena
authors.initials: M
authors.lastname: Greco
authors.forename: Antonio
authors.initials: A
authors.lastname: Malvasi
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Piccinni
authors.forename: Silvio
authors.initials: S
authors.lastname: Turano
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Grima
authors.forename: Domenico
authors.initials: D
authors.lastname: Dell' Ederam
authors.forename: Antonella
authors.initials: A
authors.lastname: Zizza
mesh_terms: D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000235:genetics* / Q000276:immunology; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D005838:Genotype; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology*; D055815:Young Adult
chemical_list: D004279:DNA, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines